Ranbaxy Denies Fraudulent Conduct Alleged By U.S. FDA As Rumors Swirl About Daiichi Deal

Ranbaxy has denied U.S. FDA allegations that it conducted "systematic fraudulent conduct" related to concealing violations of current good manufacturing practices